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Patients fail to comply with asthma medication for a variety of reasons. These range from physical inability to use
an inhaler, through simple forgetfulness, to a conscious decision not to use medication as prescribed due to internal
or cultural health beliefs or socioeconomic factors. In some patients, poor self-care because of deep-rooted
psychological factors (i.e. factors of which patients have only limited awareness) can aect compliance. Poor
doctor–patient communication can be the cause in many other individuals. Thus, there is no single solution that will
improve compliance in all patients. Simplifying the regimen or providing memory aids will be sucient for some
patients, while education or psychological counselling will be more appropriate for others. Doctors can also use a
range of communication skills to improve the way in which they present information, motivate patients and
reinforce progress. These approaches, plus respect for patients’ health beliefs and involving them in treatment
decisions, can help foster an atmosphere of mutual responsibility and concordance over medicine taking.
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Patients may fail to comply with prescribed medication
regimens for a variety of reasons. They may intend to
comply but may misunderstand or forget complicated drug
regimens. They may be physically unable to cope with
inhaler devices. Patients may also have fears about their
medication; a fear of becoming dependent on medication is
common. Many patients express concerns about possible
side eects of inhaled corticosteroids used for the treatment
of asthma (1,2). In addition, asthma patients may think
that treatment is unnecessary during symptom-free periods
(3,4). Alternatively, patients may consider the medicine to
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0954-6111/00/010002+08 $35?00/0benefits according to internal, cultural and social criteria
(4). Socioeconomic factors also play an important role (5).
A major contributor to non-compliance is poor commu-
nication between the doctor and patient. Management of a
chronic disease diers from that of an acute disease in that
it requires an ongoing partnership between doctor and
patient, which enables the treatment regimen to be
constantly fine-tuned (6). This partnership depends on
education of both healthcare providers (7,8) and patients
(9), and on doctor–patient communication. This is to
ensure that the best available information is supplied to
patients and that they are willing and able to follow the
treatment regimen at home. The partnership is hindered if
patients feel that they are wasting the doctor’s time or that
they have not been listened to, and by an inability to
understand the information given (4). In turn, patients may
omit details that they deem unimportant or embarrassing
but may be important in deciding the optimal treatment.
Clinical investigators have described compliance in
widely varying terms such as the percentage of prescribed
doses taken or the percentage of days with ‘adequate’
compliance. By whatever definition used, estimations of
compliance with inhaled respiratory medication are in-
variably poor, and are in the range of 40–50% (10,11).
Values as low as 15% have been reported (12). Long-term
compliance is a particular problem in chronic respiratory
disease. Using an electronic monitoring device to record
inhaler usage, Simmons et al. (13) showed that compliance# 2000 HARCOURT PUBLISHERS LTD
FIG. 1. The interaction of improvements in emotional and
cognitive factors with behavioural outcome.
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visits, and improved immediately after each clinic visit. This
improvement post-visit decreased with each clinic visit in a
long-term clinical trial. Similar results were obtained in a
2-yr follow-up study, with self-reported compliance con-
firmed by inhaler weights indicating a fall in compliance
from approximately 70% at baseline to 48% at 1 and 2 yr
(14). Even patients with severe disease do not necessarily
comply with their medication. Only about half of patients
requiring home nebulizer or oxygen therapy adhere to the
prescribed regimen (15–17), while 26% of patients requiring
oral steroids were non-compliant (18). A mixture of socio-
economic, demographic and personal factors appeared to
aect compliance more than symptom severity in these
patients (15,16). This prevalence of poor compliance to
medication may also aect adherence to guidelines for stepped
treatment, making the most appropriate level of treatment
dicult to judge and leading to inappropriate stepping up of
medication as a result of an apparent lack of ecacy.
A working party on medicine consumption for the Royal
Pharmaceutical Society of Great Britain has recommended
that ‘concordance’ should replace the term ‘compliance’
(19). This change in terminology is thought to reflect more
appropriately the necessary doctor–patient relationship.
The modern doctor–patient relationship is one that is based
less on unquestioning trust and more on openness and
respect. Thus, it is hoped that by improving patient
understanding there will be an increase in co-operation
and ‘compliance’. This article explores ways in which this
can be achieved.
Improved understanding of
psychological, social and cultural
issues
Thoughts, beliefs and emotions all influence behaviour to
varying degrees. Psychological, social and cultural factors
all have an impact on these aspects of the personality and
can aect compliance (1). Compliance can be aected by
socioeconomic factors. Poverty, poor family support, living
alone and belonging to a minority ethnic race have all been
associated with poor compliance (5). Better understanding
of how these issues aect compliance is required so that
helpful strategies, such as psychotherapy, motivation and
support can be investigated to help encourage compliance
in some patients.
PSYCHOTHERAPY
Psychological counselling may produce an emotional
improvement that can increase the desire and ability of
some patients to improve self-care, particularly those who
are depressed. However, studies examining the use of
psychological interventions to improve compliance have
reported only a few statistically significant improvements,
most of which were short-lived (1,19).
An ongoing randomized, controlled study at Guy’s
Hospital, London, U.K., is assessing the eectiveness ofcognitive analytical therapy in severely asthmatic patients
who are less than 70% compliant. This technique increases
patient awareness of unhelpful thought and behaviour
patterns developed in childhood and their eect on present
self-care. By coming to understand their treatment rights
and responsibilities, patients can, it is thought, break the
cycle. Improvements in feelings of self-worth and indepen-
dence may then produce positive behavioural outcomes,
such as improved compliance (Fig. 1). To date, assessment
using the Hospital Anxiety and Depression Scale (HADS)
has shown higher scores in non-compliant compared with
compliant patients. Depression was diagnosed more than
twice as often in the non-compliant group compared with
the compliant group. Significantly higher HADS depression
scores (47 vs. 32, P5005) were also observed in the non-
compliant compared with compliant group during a
prospective study of 102 asthma patients (20). Thus,
addressing depression appears to be a logical approach
for some non-compliant patients.
MOTIVATION
Motivation has been described as ‘the probability that a
person will enter into, continue and adhere to a specific
change strategy’ (21). This reflects the fact that behavioural
changes are not usually instant but involve several steps,
taken over a period of time. These steps are described in the
Stages of Change model (22). In deciding to change a
current behaviour, patients must balance the pros and cons
of the change (decisional balance) according to their
lifestyles and health beliefs. As patients move from
unawareness of any problem through contemplating a
change to actually carrying out the action, the pros increase
and the cons decrease (23,24). Once the change has been
accomplished, self-ecacy (the confidence to overcome
diculties and maintain the new behaviour pattern) is
important (25). Reinforcement of any progress and
encouragement to continue are essential during the entire
process of change, but help from healthcare providers
diers at each stage (Table 1). In the early stages of change,
emotional and cognitive factors are important to raise
consciousness and increase motivation to take the first step.
TABLE 1. Use of the stages of change model to improve compliance
Stage of change Processes in operation Patient Characteristics Action to take
Precontemplation Consciousness raising
Social liberation
Rebellion
Resignation
Rationalization
Reluctance
Provide choices
Build hope
Encourage reflection
Give information
Reinforce progress
Contemplation Consciousness raising
Social liberation
Emotional arousal
Self-re-evaluation
Open to information
Ambivalence
Provide information
Help weigh pros and cons
Increase self-ecacy
Reinforce progress
Preparation Social liberation
Emotional arousal
Self-re-evaluation
Commitment
Determination Help set goals
Provide strategies for change
Reinforce progress
Action Social liberation
Commitment
Reward
Countering
Environmental control
Helping relationships
Actively changing
Self-evaluation
Teach skills and self-management techniques
Guide attribution process
Reinforce progress
Maintenance Commitment
Reward
Countering
Environmental control
Helping relationships
At risk of lapse/relapse
Self-evaluation
Teach relapse prevention strategies
Encourage continuation
Help re-define goals
Reinforce progress
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action and avoiding relapse; defining goals and teaching
drug administration skills and relapse prevention strategies
become more important. Motivation and supplying rele-
vant information therefore need to be geared specifically to
the patient’s stage of readiness to change. However, care
must be taken not to pressure the patient as this may lead to
resistance.
Counselling guidelines based on this model have been
published by Miller et al. (26), and have proved successful
in fields such as smoking cessation (27) and exercise
motivation (28). The model has been recognized as a
potentially valuable framework for increasing compliance
(22), and a recent study in psychiatric patients has
confirmed the eectiveness of compliance therapy (29).
CULTURAL AND SOCIAL FACTORS
Many ethnic groups have their own health beliefs and
traditional remedies (30). For example, inhaled substances
are considered ‘bad’ in some eastern cultures, while oral
ones are thought of as ‘good’. Inhalers may therefore bepoorly accepted in these communities. Chinese and
Ayurvedic medicine is based on a balance between life
forces. Although western medicine is perceived as powerful
in the short-term, it is considered to cause imbalance in the
long-term. Thus, immigrant ethnic groups often mix
traditional and western medicines (31), and may discon-
tinue the western medication in favour of the traditional
remedy when acute symptoms disappear. It is unrealistic to
expect traditional medicines to be abandoned completely in
favour of western ones; compliance can only be encouraged
through education. In these groups there are also potential
language barriers, hence it is important that information is
understood.
Social factors are of particular concern when treating
children, since the entire family needs to be fully informed
and agree with the diagnosis and treatment to comply with
their physician’s advice. Poor family support has been
linked with non-compliance (5). Well-designed booklets
and videos, together with good support from healthcare
workers, can assist with family education (32).
Patients may view having asthma as a stigma, e.g. when
using inhalers in public, seeking employment or needing
time o work. The potentially negative social image of
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children and adolescents (4). However, highly technical,
state-of-the-art inhaler devices are usually popular in
adolescents, so it may be possible to increase compliance.
Explaining how treatment can result in being able to
participate in enjoyable activities may be more motivating
than discussing clinical information in this case.
Improvement of the doctor±patient
relationship
A poor doctor–patient relationship can severely hinder
compliance. Improved listening and communication skills
can assist in identifying patients’ problems and concerns,
and in delivering education, reassurance, advice and
encouragement in the most accessible and acceptable way
for each individual patient (9).
The way in which information is presented is also
important. Non-verbal behaviour, such as sitting next to
the patient or leaning forward, reduces any perceived social
distance and indicates attention. Verbal praise and encour-
agement are extremely important to patients and reward
positive disease management. Participating in interactive
conversation, using open-ended questions and providing
reassuring messages helps patients feel part of a partnership
that is working to control their condition. Tailoring
messages specifically to patients is also very important.FIG. 2. Use of medical services by asthma patients before and af
and communication skills. a: Hospitalizations; b: Non-emergenc
follow-up an episode of symptoms. (All baseline vs. follow-up).NEUROLINGUISTIC PROGRAMMING
Neurolinguistic programming is a method by which the
doctor attempts to tailor messages to each individual
patient. In neurolinguistic programming, the doctor takes
cues from the patient to establish rapport, determine what
the patient hopes to gain from the consultation and how he/
she assimilates and processes any information given.
Communication can then be structured eectively to
suggest ways to achieve the desired health outcome. For
example, while some patients welcome increased participa-
tion and control in treatment plans, others do not (33) and
require more support. Diagrams, demonstrations and
written material can be used as appropriate. The conversa-
tion should start with the problem and dispel any worries,
so that preoccupation with these does not impede taking in
new information. It can then move on to suggest ways to
improve control. Such tailored self-management strategies
have resulted in improved compliance, better inhaler
technique and reductions in symptoms and hospital visits
(34–37).
DO IMPROVED COMMUNICATION SKILLS
AFFECT PATIENT OUTCOMES?
Clark et al. (38) compared clinical outcomes of asthmatic
children treated by 42 paediatricians who had undergoneter training of their doctors in asthma treatment guidelines
y consultations; c: Emergency room (ER) visits; d: Visits to
—: Treatment; . . .: control.
FIG. 3. Compliance with separate and combined inhaled
corticosteroids and b2-agonists. : Budesonide; &:
terbuteline; &: combined.
6 K. R. CHAPMAN ET AL.training in the latest recommendations for asthma treat-
ment and communication skills with those treated by 41
control paediatricians (no training). The training signifi-
cantly increased the likelihood of prescribing inhaled anti-
inflammatory therapy, checking inhaler technique and
providing tailored guidelines, reassurance and encourage-
ment. Consequently, patients made significantly fewer
consultations (124 vs. 225, P50005) and visits after an
episode of symptoms (094 vs. 161, P50005).
Among the 72 children who started inhaled anti-
inflammatory medication during the above study, those
treated by doctors who had undergone training showed
significantly fewer asthma symptoms, and had a minimal
number of non-emergency and follow-up consultations,
hospitalizations and emergency room visits regardless of
their visit frequency at baseline. This suggested that both
the anti-inflammatory agent and education to enable
correct use of the device were needed to improve symptom
control. In contrast, control patients who often used these
services continued to do so (Fig. 2). Thus, by improving
self-management, doctor training reduced the need for
medical services by high-level users.
Practical measures to increase
compliance
Current stepped guidelines for asthma treatment involve
complex medication schedules, which alter as symptoms
increase or decrease (39–41). Persistent asthma requires
regular inhaled corticosteroid therapy to maintain control,
even if symptoms are relatively mild. As severity increases,
so does the number of regular medications. Self-monitoring
of peak flow is also recommended so that instability can be
recognized early and treatment adjusted accordingly.
Stepped treatment therefore requires compliance in many
areas but also introduces many possibilities for non-
compliance, ranging from diculty in using inhalers
through to confusion over complex monitoring and
treatment regimens. Education, training and support are
all important in assisting compliance, but a number of
practical measures can also be used.
SIMPLIFICATION OF THERAPY
Reducing dosing frequency
Medicines requiring frequent dosing are less convenient
than those with a once or twice daily schedule and may
result in reduced compliance. Coutts et al. (42) found
compliance with inhaled corticosteroids taken two-, three-
or four-times daily was 71%, 34% and 18%, respectively,
indicating that increasing the dosing frequency decreases
compliance. Mann et al. (43) observed similar results with
inhaled flunisolide; patients taking four inhalations twice
daily underdosed on 20% of study days while those taking
two inhalations four times daily underdosed 57% during
the study (P50001).Combined inhalers
Patients with moderate or severe persistent asthma are
often advised to use both inhaled corticosteroids and a
long-acting bronchodilator. Although using two regular
medications improves respiratory function (44), it increases
the complexity of the treatment regimen and creates
inconvenience. Combining the two agents in one inhaler
could improve compliance in this setting, but conflicting
results have been obtained in studies to date. Combination
inhalers containing a short-acting b2-agonist plus a
corticosteroid (45) or nedocromil sodium (46) were not
complied with more faithfully than separate inhalers under
clinical trial conditions. However, Barnes and O’Connor
(47) found that compliance with a fixed combination of
terbutaline and budesonide was the same as that obtained
with terbutaline alone and superior to that seen with
budesonide alone (Fig. 3). It is possible that this improve-
ment in compliance is the result of increased convenience
with the combination inhaler. One of the limitations of this
study is that it combined a short-acting b2-agonist plus a
corticosteroid; the eect of combining a long-acting b2-
agonist and a corticosteroid on compliance remains to be
determined.
However, one study has examined the eect of adding a
long-acting b2-agonist to existing corticosteroid therapy on
repeat prescription usage (which can be considered as an
indirect measure of compliance) of inhaled corticosteroids
in general practice (48). The addition of a long-acting b2-
agonist to on-going corticosteroid therapy increased the
proportion of inhaled corticosteroids dispensed to the
patient. This suggests that the prescription of long-acting
b2-agonists with corticosteroid therapy actually improves
compliance with inhaled corticosteroids. This may be
because patients have a greater belief in the ecacy of
their treatment when a long-acting b2-agonist dramatically
reduces symptoms and hence the need for short-acting
bronchodilator needs.
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It is sometimes assumed that switching to oral administra-
tion may improve compliance compared with the inhaled
route. However, there is little evidence to support this
assumption. Kelloway et al. (49) found significantly better
compliance with oral theophylline (79+34%) than with
inhaled sodium cromoglycate (44+34%, P=00080) or low-
dose beclomethasone dipropionate (54+43%, P=00001).
A separate study found that 70% of patients complied with
oral treatment compared with 52% for inhaled medication
(P500001) (50); however, the same dosing frequency was
not used for oral and inhaled medications. In contrast,
Allesandro et al. (51) observed better compliance with inhaled
beclomethasone dipropionate than with oral theophylline,
implying that patients do not always prefer oral medication.
Inhaled short-acting bronchodilators used as-required
have a rapid onset of eect for acute relief of symptoms.
For example, oral terbutaline or salbutamol produce peak
bronchodilatation about 25–3 h after administration; but
the same eect is achieved in only 10–15 min after
inhalation of either medication (52). Such rapid relief of
symptoms provides strong reinforcement to the patient and
encourages further use. Short-term side eects such as
tremor and haemodynamic eects (53) also occur quickly,
and may be viewed by some patients as a signal that the
medication is working. In addition, when a metered-dose
inhaler (MDI) is used to deliver a drug, the taste of the
formulation and the propellant and its physical impact on
the oropharynx is more obvious than when using delivery
devices such as the Turbuhaler1 (AB Draco, Lund,
Sweden) or a MDI plus spacer. The oropharyngeal
sensation reassures patients that the device is working and
that they have received their medication. As a consequence,
there may be reduced compliance with a MDI plus spacer
even though this results in improved drug delivery to the
lungs (54). In a study comparing two dierent dry powder
inhalers, Diskus1 (GlaxoWellcome, London, U.K.) inhaler
(which incorporates a small amount of lactose with each
dose) and the Turbuhaler1, one of the main reasons that
patients preferred the Diskus1 was because they were able
to perceive the dose being delivered (55).
In current treatment guidelines, the inhaled route is
preferred to oral administration, as the former is considered
a safe and rapidly eective topical therapy. The oral
leukotriene modifiers are mainly recommended as add-on
therapy to inhaled corticosteroids. Asthma patients almost
always need to carry an inhaler containing rescue broncho-
dilator medication, and if disease is of moderate or greater
severity, complete symptom control is likely to require
concurrent inhaled preventative medication. Hence, it is
possible that oral medication used in conjunction with
inhaled corticosteroids may lead to reduced compliance
because of increases in regimen complexity.
Type of inhaler
Poor inhaler technique is a major reason for unintentional
underdosing and can easily be interpreted as non-compli-ance (3). Many patients have problems using MDIs and
may benefit from repeated training or easier to use inhalers.
MDIs require co-ordination of device actuation and
inhalation, but dry powder inhalers are breath-actuated
devices and may be easier for children and the elderly to
use. Comparisons of two newer dry powder inhalers, the
Diskus1 and Turbuhaler1 inhalers, have shown that
patients (particularly the elderly) preferred the Diskus1
inhaler, finding it significantly easier to hold and use
(55,56). However, whether this increased preference results
in improved compliance has yet to be determined.
Memory aids
Memory aids such as reminder notes or diaries can be
helpful in reinforcing compliance. Electronic diaries are
available, and provide a more accurate record than written
records (57). Electronic dosage recorders such as the
Chronolog1 (Forefront Technologies Inc., Lakewood,
Co, U.S.A.) (42,58), Turbuhaler1 Inhalation Computer
(59,60) and Doser1 (Meditrack Products, Hudson, Ma,
U.S.A.) (61) are also now available in several countries.
These devices display the number of doses remaining in the
inhaler and record usage at specific times over a set time
period. Newer devices such as the Diskus1 inhaler have
built-in dosage counters. Besides acting as a memory aid,
these counters can provide doctors and patients with
feedback on medication administration, which can be used
at consultations to improve compliance (13,62).
Conclusions
Patients can fail to comply with asthma medication for a
variety of physical, personal, cultural and socioeconomic
reasons. In some patients, a general lack of self-care due to
psychological outlooks developed during childhood can
aect compliance. Many others will fail to comply because
of poor doctor–patient communication. Thus, there is no
single solution that will improve compliance in all patients.
Simplifying the treatment regimen or providing memory
aids will be sucient for some patients, while education or
psychological counselling will be more appropriate for
others. Doctors can also use a range of communication
skills to improve the way in which they present informa-
tion, motivate patients and reinforce progress. This may
involve the use of diagrams, leaflets, reports and written
home-management plans as well as discussion. These
approaches, plus respect for patients’ health beliefs and
involving them in treatment decisions, will foster an
atmosphere of mutual responsibility, leading to concor-
dance over medicine taking. When focusing on compliance
it is important not to lose sight of clinical outcome. For
example, it is better to achieve complete asthma control
with an eective medication taken less than that prescribed
than it is to achieve perfect compliance with an ineective
medication that fails to control the disease.
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